Xention and Grünenthal enter Drug Discovery Collaboration in Ion Channel Research
Research collaboration to focus on development of novel pain therapeutics
XENTION LTD announced that it has entered into a Research Agreement with the Grünenthal Group. Under the terms of the Agreement, Xention and Grϋnenthal will combine their respective expertise in ion channel drug discovery and pain therapy to collaborate in the identification of new drugs to treat chronic pain. Xention will apply its proprietary ion channel drug discovery platform to the design, synthesis and in vitro assessment of small molecules which target an ion channel of key pathophysiological importance in pain and against which selective ligands have not previously been developed. Grünenthal will add key expertise to all discovery aspects and assume responsibility to (pre)-clinical development and worldwide commercialization of potential new pharmaceutical products arising from the collaboration.
Grünenthal will fund the two-year research programme in its entirety, and Xention will also receive an upfront fee and be eligible for milestone fees on meeting specified discovery objectives and on the achievement of development and regulatory goals.
“We look forward to working with Xention and to accessing the wide range of ion channel drug discovery technologies Xention possesses. We anticipate that the collaboration will result in the identification of novel drugs with high clinical and commercial potential” said Prof. Eric-Paul Pâques, President Grünenthal Innovation & Chief Alliance Officer, Vice-Chairman of the Corporate Management Board of the Grünenthal Group.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Molecular switch may serve as new target point for cancer and diabetes therapies
HIV/AIDS long-term costs high - and unaffordable to most-affected countries
Part of hagfish slime mystery solved

Effects of chemical mixtures: Neurotoxic effects add up - Study demonstrates for the first time the toxicological relevance of chemical mixtures as they occur in humans

Innovative approach to treat autism spectrum disorders - University of Basel spin-off Translation-X receives Venture Kick funding

Shifting meetings, conventions online curbs climate change - The annual carbon footprint for the global event and convention industry is on par with the yearly greenhouse gas emissions of the entire U.S.
Photocure announces positive results of Phase 2B study evaluating Visonac in acne
Dental_porcelain
Rockeby awarded bird flu tests tender from Middle East
Rentschler focuses on biotechnology

How cancer genes become independent - Study sheds light on the mysterious evolution of DNA rings
